Digestive Disease Week

The median exposure of vedolizumab was 1.93 years and lower incidence rates were found for infliximab or adalimumab.

RBX2660 showed similar efficacy and safety in treating patients with and without immunocompromised conditions.

Both the incidence and prevalence of inflammatory bowel disease is growing among the older population.

There is no additional risk of developing new cancers for patients treated with IBD medications.

RBX2660 was the first ever live microbiota therapeutic to gain approval from the FDA for rCDI.

Guselkumab is currently being evaluated as a treatment for both ulcerative colitis and Crohn's disease.

A redo surgery often improves the quality of life in a number of ways for patients with ulcerative colitis.

Pregnant women with celiac disease were not only at a higher risk of several pregnancy and delivery related complications, but also less likely to have a full-term uncomplicated delivery compared to the cohort without celiac disease.

There was a reduction in medical costs that offset the increased pharmacy costs in the patients who were treated with rifaximin.

In 2022, dupilumab became the first treatment approved by the US Food and Drug Administration for the treatment of patients with EoE.

In the induction trial, guselkumab resulted in a higher rate of clinical remission, as well as symptomatic remission, clinical response, endoscopic improvement, and histo-endoscopic mucosal improvement at week 12.

The linaclotide group had significant improvements from baseline in the 12 week SBM frequency rate and 12-week stool consistency.

Guselkumab induction treatment resulted in significantly greater proportions of patients achieving symptomatic remission, clinical response, endoscopy improvement, and histo-endoscopic mucosal improvement at week 12 and symptomatic remission at week 4 compared to placebo.

The lowest screening completion rate was in the colonoscopy invitation group at 14.5% and the patients offered a choice were more likely to complete screening of any kind, compared to either group of patients offered only 1 screening modality.

The mean number of required reinterventions was significantly lower in the patients who received a direct endoscopic necrosectomy at index session when compared with patients who received the step-up treatment approach.

There was a significant reduction in severity score for diarrhea, constipation, abdominal pain, epigastric pain, bloating, vomiting, and acid reflux in participants who reported digestive problem improvements followed by SIM01 treatment.

Regardless of a prior history of swallowed topical corticosteroids, dupilumab was proven to be an effective treatment in patients with eosinophilic esophagitis.

RBX2660 can be administered through a colonoscopy or rectally.

RBX2660 was originally approved by the FDA in 2022 and came to market in January 2023.

Rates of key safety events, such as malignancies and major adverse cardiovascular events, were comparable among patients receiving placebo and ustekinumab.

Recent studies have indicated that using adenoma per colonoscopy as a metric could help better forecast the risk of colon cancer.

Patients with IBD who were treated with advanced therapies who obtained clinical remission had 1.6 times more likely to maintain remission when compared with those who achieved clinical response without remission.

A proportion of patients reported triggering or worsening symptoms after a meal, with the largest proportion experiencing bloating or distention, followed by abdominal pain or discomfort, and epigastric pain.

No statistically significant differences in infusion reaction, serious reaction, or immunogenicity rates were identified between patients switching to an infliximab biosimilar and those who continued treatment on the originator.

The risk of developing high grade dysplasia or esophageal adenocarcinoma was higher in patients with Barrett’s esophagus with immunosuppressant medication use.

No statically significant differences in ESR, CRP, TNF levels, and albumin were observed pre- and post-switch from the infliximab originator to the biosimilar.

At the 12-month mark, 52% of patients in the axSpA cohort and 76% of those in the IBD cohort achieved clinical remission.

Small molecule therapies offer patients with mild or moderate inflammatory bowel disease a much cheaper alternative to biologics.

Artificial intelligence is being used to help detect polyps for patients undergoing a colonoscopy.

A diet that is high in sugar, fried foods, and lacks vegetables increases the risk of pediatric inflammatory bowel disease.